Is peri-transplant blood transfusion associated with worse transplant outcomes? A retrospective study

Table 1 Baseline characteristics of both the transfusion and non-transfusion groups, n (%)

	Total cohort, 105	Non-transfusion, 51 (48.6%)	Transfusion, 54 (51.4%)	P value
Age (mean ± SD)	39.7 ± 14.5	40.5 ± 13.9	38.9 ± 15.1	0.583
Gender
Female	28 (26.7)	10 (19.6)	18 (33.3)	0.127
Male	77 (73.3)	41 (80.4)	36 (66.7)
Type of transplantation
LRKTx	84 (80)	43 (84.3)	41 (75.9)	0.566
LURKTx	15 (14.3)	6 (11.8)	9 (16.7)
DDKTx	6 (5.7)	2 (3.9)	4 (7.4)
HLA mismatch	3 (1-4)	3 (0-4)	3 (2-4)	0.152
Cause of ESRD
Diabetes	18 (17.1)	7 (13.7)	11 (20.4)	0.331
GN	26 (24.8)	11 (21.6)	15 (27.8)
Hypertension	18 (17.1)	12 (23.5)	6 (11.1)
PCKD	1 (1)	1 (2)	0 (0)
Urological	7 (6.7)	2 (3.9)	5 (9.3)
Other	35 (33.3)	18 (35.3)	17 (31.5)
Donor's age	33 ± 8.6	32.4 ± 8.4	33.5 ± 8.8	0.562
Induction therapy
ATG	42 (40)	21 (41.2)	21 (38.9)	1
Basiliximab	62 (59)	30 (58.8)	32 (59.3)
No induction	1 (1)	0 (0)	1 (1.9)
Maintenance immunosuppression
CNI used tacrolimus	105 (100)	51 (100)	54 (100)
Average CNI level	7 (6-8)	7 (6-8)	7 (6-8)	0.743
Antimetabolite used (MMF)	105 (100)	51 (100)	54 (100)

LRKTX: Living-related kidney transplantation; LURKTx: Living non-related kidney transplantation; DDKTX: Deceased-donor kidney transplantation; HLA: Human leucocyte antigen; ESRD: End-stage renal disease; GN: Glomerulonephritis; PCKD: Polycystic kidney disease; ATG: Antithymocyte globulin; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil.